To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
-
Eif4g1 KO
Mice carrying a targeted Eif4g1 mutation in which exons 24 through 28 are deleted. RRID:IMSR_JAX:024521
-
Lentiviral eGFP-LRRK2 (wild-type)
Lentiviral vector encoding wild-type LRRK2 and eGFP. Lentiviral eGFP available as a control in Reporter section.
Please note: This viral vector is not intended for in vivo use.
-
Alpha-Synuclein Antibody
Rabbit monoclonal antibody directed against wild-type human alpha-synuclein. The antibody was mapped to amino acids 118-123 (VDPDNE).
-
Wild Type Human Alpha-Synuclein Mouse
Mice express a wild-type human alpha-synuclein gene directed by its endogenous promoter/enhancer regions on the BAC transgene. RRID:IMSR_JAX:018442
-
LRRK2 Antibody (MJFF2)
Rabbit monoclonal antibody directed against wild-type LRRK2. The antibody was mapped to the LRR domain of LRRK2 (AA 1035-1239).
-
LRRK2 Wild-type Mouse
Mice express a wild-type human LRRK2 gene directed by its endogenous promoter/enhancer regions on the BAC transgene. The human LRRK2 protein expression is approximately 5-fold over endogenous mouse LRRK2. RRID:IMSR_JAX:013725
-
DOX-Inducible iPSC-Derived Dopamine Neuron
Inducible iPSC line in which addition of doxicycline to the media stimulates differentiation into dopamine neurons with 90% purity in a matter of days.
Estimated Availability: Mid 2026
-
Parkin/PINK1 Double KO Rat
Breeding of the CRISPR Parkin KO Sprague Dawley rat with the CRISPR PINK1 KO Sprague Dawley rat to create a line with homozygous deletion of both genes.
Estimated Availability: Mid 2026
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic